Heparin Market Report (2022 to 2030) – Baxter, Pfizer Inc., B. Braun Melsungen AG, GlaxoSmithKline Plc, Sanofi and Sandoz

Newark, New Castle, USA, Jan. 23, 2023 (GLOBE NEWSWIRE) — As per the report published by Growth Plus Reports the Global Heparin Market was estimated at US$ 9.1 billion in 2021 and is expected to surpass a valuation of US$ 12.18 billion by 2030, progressing at a CAGR of 3.30% from 2022 to 2030. The report provides a detailed analysis of top winning strategies, drivers & opportunities, competitive scenario, wavering market trends, market size, statistics & estimations, and major investment pockets.

Download PDF Brochure of Heparin Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.growthplusreports.com/inquiry/request-sample/heparin-market/8074

The global heparin market is primarily driven by increasing demand for heparin in surgical procedures and the rising prevalence of cardiovascular diseases. Additionally, increasing numbers of key players, the emerging diagnostic industry with multiple uses of heparin, and growing awareness about multiple medical uses of heparin are also contributing to the growth of the global heparin market.

Heparin is an anticoagulant that is prescribed to avoid thrombosis and treat a variety of disorders, including deep vein thrombosis and atrial fibrillation. Heparin is also used to avoid blood clots from developing in individuals with certain medical problems or who are having particular surgical treatments that raise the risk of blood clot formation. As heparin is used to prevent blood clotting in the arteries, however, it cannot be used to lessen the proportion of clots that have already formed. Heparin has a major application in angioplasty and angiography surgery to prevent blood clots from forming in catheters.

Growth Drivers

The increasing prevalence of the cardiovascular disease is driving the growth of the global heparin market. In June 2021 the World Health Organization stated that cardiovascular diseases (CVDs) are the leading cause of death worldwide, killing approximately 17.9 million people each year. CVDs are a collection of heart and blood vessel illnesses that include coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other ailments. Heart attacks and strokes account for more than four out of every five CVD fatalities, with one-third of these deaths occurring in those under the age of 70. The most important behavioral risk factors for heart disease and stroke include a poor diet, physical inactivity, cigarette use, and problematic alcohol consumption. Individuals may experience the impacts of behavioral risk factors like high blood pressure, high blood glucose, high blood lipids, and being overweight or obese. 

The global heparin market has been analyzed from five different perspectives – Type, Source, Application, End User, and Region

Excerpts from ‘by Type’

The global heparin market based on type has been segmented into:

  • Low Molecular Weight Heparin (LMWH)
  • Unfractionated Heparin (UFH)

Low molecular weight heparin dominates the global heparin market primarily because of its significant therapeutic potency, superior bioavailability, prolonged half-life and its ability to be administered subcutaneously. Furthermore, the excellent safety and low toxicity of heparin are also driving the growth of the segment in the market.

Excerpts From ‘by Source’

The global heparin market based on the source has been segmented into porcine and bovine. Porcine dominates the global heparin market due to rising demand for porcine for low molecular weight heparin extraction and cheap availability of raw material. However, due to the limited acceptability of porcine-based products among the Islamic and Jewish populations, the market for the porcine segment is expected to restrain to a certain extent.

Excerpts From ‘by Application’

The global heparin market based on the application has been segmented into:

  • Heart Attacks
  • Stroke
  • Deep Vein Thrombosis & Pulmonary Embolism
  • Atrial Fibrillation
  • Others

Heat attacks dominate the global heparin market owing to the increased frequency of cardiovascular disorders and the increasing number of heart attacks. Furthermore, the significant therapeutic efficacy of heparin in the treatment of cardiovascular illnesses is adding to the growth of the global heparin market. According to the Centers for Disease Control and Prevention, heart disease is the top cause of mortality in the United States. Every 34 seconds, a person in the United States dies from cardiovascular disease. Heart disease claimed the lives of over 697,000 people in the United States in 2020.

Browse full report with detailed TOC at: https://www.growthplusreports.com/report/heparin-market/8074

Excerpts from ‘by Region Segmentation

The global heparin market has been segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

The global heparin market is dominated by North America, followed by Asia Pacific. The large share of North America in the global market is attributed to the increasing prevalence of cardiovascular diseases in the region, increasing numbers of hospitals and clinics, and increasing demand for cardiac surgical procedures. Asia Pacific is also expected to show the highest growth in upcoming years owing to the increasing geriatric population, high prevalence of cardiovascular disease, and emerging diagnostic industry.

Excerpts from ‘Competitive Landscape’

The prominent players operating in the global heparin market are:

  • Opocrin S.p.A.
  • Baxter
  • Pfizer Inc.
  • Bioiberica S.A.U
  • Fresenius SE & Co. KGaA
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
  • B. Braun Melsungen AG
  • Dr. Reddy’s Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Sanofi
  • Sandoz
  • LEO Pharma A/S
  • Aspen Holdings


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Inquiry Before Buying: https://www.growthplusreports.com/inquiry/before-buying/heparin-market/8074

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] Phone no: +1 888 550 5009 Web: https://growthplusreports.com/  

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Mango Bunch takes no editorial responsibility for the same.